A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active:	Yes
Cancer Type:	Esophogeal Cancer Stomach/ Gastric Cancer Unknown Primary	NCT ID:	NCT06356311
Trial Phases:	Phase III	Protocol IDs:	2870-015 (primary) NCI-2024-06314 2023-505423-31 2023-505423-31-00 jRCT2031240133 MK-2870-015 U1111-1291-7109
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp and Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06356311

Summary

This study will compare how safe and effective sacituzumab tirumotecan is versus the
treatment of physician's choice (TPC) in participants with advanced/metastatic
gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab
tirumotecan is superior to TPC with respect to Overall Survival (OS).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.